Journal
BONE MARROW TRANSPLANTATION
Volume 45, Issue 2, Pages 269-275Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/bmt.2009.142
Keywords
plerixafor; multiple myeloma; non-Hodgkin's lymphoma; CD34+cells; mobilization; tumor cell contamination
Categories
Funding
- AnorMED, Inc. now Genzyme Corporation, Cambridge, MA, USA
Ask authors/readers for more resources
This report describes the first investigational use of plerixafor in Europe and the determination of tumor cell mobilization by polymerase chain-reaction after plerixafor treatment in a subset of patients with multiple myeloma (MM). Thirty-five patients (31 MM and 4 NHL) received granulocyte colony-stimulating factor (G-CSF) (10 mu g/kg) each morning for 4 days. Starting the evening of Day 4, patients recieved plerixafor 0.24 mg/kg. Apheresis was initiated 10-11 h later, in the morning of Day 5. This regimen of G-CSF treatment each morning before apheresis and plerixafor treatment in the evening was repeated for up to 5 consecutive days. Mobilization with plerixafor and G-CSF resulted in a median 2.6-fold increase in peripheral blood (PB) CD34+ cell count compared with before plerixafor treatment. All patients collected >= 2 x 10(6) CD34+ cells/kg and 32 of 35 patients collected >= 5 x 10(6) CD34+ cells/kg. After plerixafor treatment, 3 of 7 patients had a small increase and 4 of 7 patients had a small decrease in PB tumor cells. No G-CSF was given post transplant. The median number of days to polymorphonuclear leukocyte and platelet engraftment was 14.0 and 11.0, respectively. There were no reports of graft failure. Plerixafor was generally well tolerated. Mobilization of PB CD34+ cells was consistent with previous clinical trials. The addition of plerixafor did not significantly increase the relative number of PB MM tumor cells. Bone Marrow Transplantation (2010) 45, 269-275; doi:10.1038/bmt.2009.142; published online 13 July 2009
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available